RxDoctor Payments Data

Tanweer Memon, MD

Internal Medicine · Port Charlotte, FLNPI 1053304774

Payments from drug & device makers

$225in general payments, 2019–2025

Across 7 payments — averaging $32.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardiovascular Systems Inc.$105
  • Amgen$29
  • Si-bone, Inc.$27
  • Collegium Pharmaceutical, Inc.$25
  • Pfizer$23
  • Agepha Pharma FZ LLC$16

What the payments were for

  • Food & beverage$225100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Cardiovascular Systems Inc.1$105
Amgen(2 entities)2$29
Si-bone, Inc.1$27
Collegium Pharmaceutical, Inc.1$25
Pfizer1$23
Agepha Pharma FZ LLC1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$225 in reported general payments places this provider in the 40th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$360,368
Medicare patients
388
Services billed
5,384

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase38$216,221
EliquisApixaban159$181,492
LinzessLinaclotide103$123,179
ZenpepLipase/Protease/Amylase26$121,591
OzempicSemaglutide99$120,477
Trelegy ElliptaFluticasone/Umeclidin/Vilanter110$99,784
VascepaIcosapent Ethyl77$70,164
TrulicityDulaglutide38$62,168
JardianceEmpagliflozin50$60,377
JanuviaSitagliptin Phosphate39$45,723
MounjaroTirzepatide32$40,337
EntrestoSacubitril/Valsartan35$40,194
Breztri AerosphereBudesonide/Glycopyr/Formoterol31$38,291
Oxycodone Hcl870$32,279
RestasisCyclosporine17$31,928

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$23$200,583178 claims
Collegium Pharmaceutical, Inc.Xtampza Er$25$22,01433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Port Charlotte

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →